| 產(chǎn)品編號(hào) | bs-1244R-PE |
| 英文名稱(chēng)1 | Rabbit Anti-Cytokeratin 1/PE Conjugated antibody |
| 中文名稱(chēng) | PE標(biāo)記的細(xì)胞角蛋白1抗體 |
| 別 名 | Cytokeratin 1; 67 kDa cytokeratin; CK 1; CK1; Cytokeratin1; EHK1; Hair alpha protein; K 1; K1; Keratin 1; Keratin type II cytoskeletal 1; Keratin1; KRT 1; KRT1A; K2C1_HUMAN; Keratin, type II cytoskeletal 1; Cytokeratin-1; CK-1; Keratin-1; Type-II keratin Kb1. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞 激酶和磷酸酶 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rabbit, (predicted: Rat, Dog, Cow, Horse, ) |
| 產(chǎn)品應(yīng)用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 70kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Cytokeratin 1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the spinous and granular layers of the epidermis with family member KRT10 and mutations in these genes have been associated with bullous congenital ichthyosiform erythroderma. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq]. Function: May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (RACK1/GNB2L1). In complex with C1QBP is a high affinty receptor for kininogen-1/HMWK. Subunit: Heterotetramer of two type I and two type II keratins. Keratin-1 is generally associated with keratin-10. Interacts with ITGB1 in the presence of GNB2L1 and SRC, and with GNB2L1. Interacts with C1QBP; the association represents a cell surface kininogen receptor. Subcellular Location: Cell membrane. Note=Located on plasma membrane of neuroblastoma NMB7 cells. Tissue Specificity: The source of this protein is neonatal foreskin. The 67-kDa type II keratins are expressed in terminally differentiating epidermis. Post-translational modifications: Undergoes deimination of some arginine residues (citrullination). DISEASE: Defects in KRT1 are a cause of epidermolytic hyperkeratosis (EHK) [MIM:113800]. An autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop. Defects in KRT1 are the cause of ichthyosis hystrix Curth-Macklin type (IHCM) [MIM:146590]. IHCM is a genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks. Defects in KRT1 are a cause of palmoplantar keratoderma non-epidermolytic (NEPPK) [MIM:600962]. NEPKK is a dermatological disorder characterized by focal palmoplantar keratoderma with oral, genital, and follicular lesions. Defects in KRT1 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months. Defects in KRT1 are the cause of palmoplantar keratoderma striate type 3 (SPPK3) [MIM:607654]; also known as keratosis palmoplantaris striata III. SPPK3 is a dermatological disorder affecting palm and sole skin where stratum corneum and epidermal layers are thickened. There is no involvement of non-palmoplantar skin, and both hair and nails are normal. Similarity: Belongs to the intermediate filament family. Database links: Entrez Gene: 3848 Human Entrez Gene: 16678 Mouse Omim: 139350 Human SwissProt: P04264 Human SwissProt: P04104 Mouse Unigene: 80828 Human Unigene: 183137 Mouse Unigene: 31789 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 結(jié)構(gòu)蛋白（Structural Proteins） 細(xì)胞角蛋白常用于腫瘤細(xì)胞的分化、增殖及轉(zhuǎn)移方面的研究。有學(xué)者認(rèn)為：在腫瘤細(xì)胞分化過(guò)程中有細(xì)胞角蛋白的表達(dá)，把細(xì)胞角蛋白作為腫瘤干細(xì)胞的標(biāo)志物。陽(yáng)性部位：主要在胞漿。CK119， CK8， CK19同源. |
| 產(chǎn)品圖片 |
Blank control (blue line): Hela cells(blue).
Primary Antibody (green line): Rabbit Anti-Cytokeratin 1/FITC Conjugated antibody (bs-1244R-PE)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG-PE.
Protocol
The cells were fixed with 70% ice-cold methanol overnight at 4℃ . The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature.Acquisition of 20,000 events was performed.
|
